Advertisement

Pharmaceutical Chemistry Journal

, Volume 39, Issue 6, pp 329–332 | Cite as

Beta-2 Lgonists for Inhalation in the Form of Dry Powders

  • T. N. Garkavaya
  • N. P. Petrugova
  • S. Ya. Skachilova
  • V. M. Pavlov
  • A. S. Sokolov
  • Yu. A. Ershov
  • E. V. Shilova
Article
  • 29 Downloads

Abstract

Popular ready-to-use β2-agonist preparations (in particular, salbutamol) available in the form of dry powders for inhalation are reviewed. Examples of the preparation of drug powders for inhalation are given and the specific features of physicochemical, structural, mechanical, and technological properties of the products are considered. The role of auxiliary substances in such preparations is discussed, and the use of a new auxiliary substance (sodium benzoate) instead of lactose is described.

Keywords

Sodium Organic Chemistry Lactose Salbutamol Technological Property 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    D. Bellamy, Why is salbutamol such a popular drug? 12, 33–35 (1991).Google Scholar
  2. 2.
    M. Johnson, Lung. Suppl., 2, 115–119 (1990).Google Scholar
  3. 3.
    A. E. Tattersfield, Br. Med. Bull., 48, 190–204 (1992).PubMedGoogle Scholar
  4. 4.
    A. I. Sinopal'nikov and I. L. Klyachkina, Ros. Med. Zh., 10(5), 34–41 (1997).Google Scholar
  5. 5.
    I. D. Apul'tsina, A. S. Sokolov, T. L. Pashkova, et al., Pulmonologiya, 9(2), 59–65 (1999).Google Scholar
  6. 6.
    S. L. Babak and A. G. Chuchalin, Ros. Med. Zh., 6(17), 27–36 (1998).Google Scholar
  7. 7.
    European Pharmacopoeia. Preparations for Inhalation. European Pharmacopoeia Supplement., 2001:2.9.18.Google Scholar
  8. 8.
    S. N. Avdeev, Ros. Med. Zh., 10(5), 13–19 (2002).Google Scholar
  9. 9.
    H. Chrystyn, Respir Med., 91, 17–19 (1997).PubMedGoogle Scholar
  10. 10.
    UK Patent No. 2107715; Chem. Abstr., 95, 1234 (1983).Google Scholar
  11. 11.
    U. B. Patel, J. Pharm. Pharmacol, 37, 108–111 (1985).Google Scholar
  12. 12.
    FRG Patent No. 2943658; Chem. Abstr., 90, 9861 (1980).Google Scholar
  13. 13.
    M. Vidgren, A. Karkjainen, P. Karjalainen, et al., Pulmonologiya, 1(4), 37–43 (1991).Google Scholar
  14. 14.
    J. Karpel, Adv. Therapy, 17, 283–287 (2000).Google Scholar
  15. 15.
    “Workshop on Medical Aerosol,” Medical Way, 1(9), 158–159 (1984).Google Scholar
  16. 16.
    US Patent No. 6053960 (2003).Google Scholar
  17. 17.
    UK Patent No. 2008725; Chem. Abstr., 92, 13241 (1981).Google Scholar
  18. 18.
    UK Patent No. 2105189; Chem. Abstr., 95, 24341 (1983).Google Scholar
  19. 19.
    US Patent No. 5478578; Chem. Abstr., 122, 2138 (1995).Google Scholar
  20. 20.
    European Patent No. 0239798; Chem. Abstr., 115, 19364 (1987).Google Scholar
  21. 21.
    UK Patent No. 4103174; Chem. Abstr., 134, 17241 (2001).Google Scholar
  22. 22.
    US Patent No. 5972388; Chem. Abstr., 130, 24390 (1999).Google Scholar
  23. 23.
    D. Kenyon, T. Yang, and A. Kaufman, in: Respiratory Drug Delivery VII, R. N. Dalby, P. R. Byron, and S. J Farr (eds.), Serentec Press (2000), Vol. 1, pp. 495–498.Google Scholar
  24. 24.
    D. Kenyon, Am. J. Respir. Crit. Care. Med., 163, A440 (2001).Google Scholar
  25. 25.
    T. Yang and D. Kenyon, in: Respiratory Drug Delivery VII, R. N. Dalby, P. R. Byron, and S. J Farr (eds.), Serentec Press (2000), Vol. 2, pp. 503–506.Google Scholar
  26. 26.
    T. T. Yang, S. Li, B. Wyka, and D. Kenyon, J. Aerosol Med., 14, 487–494 (2001).CrossRefPubMedGoogle Scholar
  27. 27.
    B. Fan, T. Yang, and D. Kenyon, Am. J. Respir. Crit. Care. Med., 161, A456 (2000).Google Scholar
  28. 28.
    European Patent No. 0260241; Chem. Abstr., 117, 14213 (1988).Google Scholar
  29. 29.
    International Patent No. 87/05803; Chem. Abstr., 115, 9613 (1987).Google Scholar
  30. 30.
    International Patent No. 87/07502; Chem. Abstr., 115, 742513 (1987).Google Scholar
  31. 31.
    International Patent No. 88/011657; Chem. Abstr., 117, 3295 (1988).Google Scholar
  32. 32.
    European Patent No. 0145240; Chem. Abstr., 97, 47423 (1984).Google Scholar
  33. 33.
    A. V. Emel'yanov and T. E. Elizarova, Pulmonologiya, 13(1), 31–39 (2003).Google Scholar
  34. 34.
    S. N. Avdeev, Ros. Med. Zh., 9(21), 75–81 (2001).Google Scholar
  35. 35.
    L. Knight and J. Fletcher, Infect. Diseas., 123, 371–377 (1971).Google Scholar
  36. 36.
    C. Frank and M. D. Voest, Ann. Allerg., 43(4), 205–210 (1979).Google Scholar
  37. 37.
    RF Patent No. 2054932 (1992); Byull. Izobret., No. 6 (1996).Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • T. N. Garkavaya
    • 2
  • N. P. Petrugova
    • 1
  • S. Ya. Skachilova
    • 1
  • V. M. Pavlov
    • 2
  • A. S. Sokolov
    • 3
  • Yu. A. Ershov
    • 4
  • E. V. Shilova
    • 1
  1. 1.All-Russia Scientific Center for Safety Testing of Biologically Active SubstancesMinistry of Public Health of the Russian FederationStaraya Kupavna, Moscow RegionRussia
  2. 2.Pulmomed CompanyMoscowRussia
  3. 3.Institute of PulmonologyMoscowRussia
  4. 4.Sechenov Moscow Medical AcademyMoscowRussia

Personalised recommendations